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Abstract
Background—Falls are common in the elderly, especially in those with cognitive impairment. 
The elderly are often treated with several medications which may have both beneficial and 
deleterious effects. The use and type of medication in Alzheimer’s patients and association with 
falls is limited.
Objective—We examined the association between falls and medication use in the Alzheimer’s 
Disease Neuro-Imaging Initiative (ADNI).
Methods—Diagnosis, demographics, medication use, apolipoprotein E4 allele status and 
functional activity level at baseline were gathered for 810 participants enrolled in ADNI including 
healthy controls and subjects with mild cognitive impairment or Alzheimer’s. Adverse event fall 
reports were tabulated. Baseline characteristics were compared between subjects with and without 
one or more falls. Cox proportional hazards models were conducted to evaluate the association 
between subject characteristics and hazard of first fall.
Results—Age (p<0.0001), functional activities questionnaire (p=0.035), Beers list (p=0.0477) 
and medications for treating cognitive symptoms of Alzheimer’s (p=0.0019) were associated with 
hazard of fall in the univariate model. In the final multivariate model, after adjusting for covariates, 
Alzheimer’s medication use (p=0.0005) was associated with hazard of fall. Medication was 
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changed after an adverse fall event by the clinician in 9% of the falls. About 7% of the falls were 
reported as serious adverse events and 6% were reported to be severe.
Conclusion—We found a significant association between use of symptomatic medication 
treating cognitive symptoms in Alzheimer’s disease and hazard of fall after adjusting for age and 
Beers list medication use. Additional pharmaco-vigilance of the association between falls and 
Alzheimer’s medication use is warranted.
Background
Falls are common in the elderly, especially in those with cognitive impairment such as 
Alzheimer’s disease (AD)(1). The elderly are often treated with multiple medications which 
may have both beneficial and adverse effects but polypharmacy has been generally 
associated with increased incidence of adverse events in the elderly (2). Many medications 
have been implicated in increasing fall risk in the elderly including antidepressants, 
antipsychotic and sedatives (3). It has been suggested that cholinesterase inhibitors (ChEIs) 
can improve gait and balance by enhancing attention and executive function, leading to a 
reduction in falls (4, 5). Despite the increasing use of ChEIs and N-methyl-D-aspartate 
receptor antagonists (memantine) in treatment of mild cognitive impairment (MCI) the stage 
that immediately precedes AD and other dementias and AD, data on the association between 
Alzheimer’s medication use and falls is limited. We tested the hypothesis that there is a 
positive association between cholinesterase inhibitor and/or memantine use and falls in the 
participants of the Alzheimer’s Disease Neuro-imaging initiative (ADNI) cohort.
Methods
ADNI is a large cohort study designed to test how neuroimaging, genetic, and clinical 
markers potentially predict the progression of MCI. More than 800 voluntary participants 
were recruited from 59 medical and/or academic sites across the United States and Canada, 
including 400 patients meeting Petersen criteria (6) for MCI, 184 mild stage AD, and 226 
healthy controls, aged 55–90 years. Exclusion criteria restricted some types of medication 
use among subjects during the study period (7).
Data on baseline diagnosis, demographics, medication use, apolipoprotein E4 (ApoE4) allele 
status, and functional activity level (a measure of disease severity), were collected from the 
ADNI clinical database (download version February 02, 2011) for 810 participants enrolled 
in ADNI. Adverse events were based on subject self and/or informant report at every follow 
up. Adverse events were recorded by ADNI clinical staff in the adverse events database as 
free text. Adverse event fall reports were defined as any free text field containing the word 
“fall,” and tabulated by subject and date. Each adverse event was also coded by ADNI 
clinical staff for severity (incapacitating, with inability to work or perform normal daily 
activity) and seriousness (fatal, immediately life-threatening, permanent/substantial 
disability, requires or prolongs inpatient hospitalization (acute), suggests any significant 
hazard, contraindication, side effect or precaution that may be associated with the use of a 
study procedure, or regarded by the investigator as a serious adverse event). Diagnosis was 
defined as early AD, MCI or normal cognition. Age and education were measured in years. 
Medication use was identified for each ADNI participant. Beers list medication use was 
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determined for each subject as described previously (2). The Beer’s list, which was 
generated by experts in pharmacology, identifies medications which may be potentially 
inappropriate for use in adults 65 years and older for various reasons such as sedation, 
cardiovascular risk and mechanism of elimination (8). Finally, the use of donepezil, 
rivastigmine, galantamine, or memantine, as well as therapy with combinations of these 
drugs was tabulated for each participant at baseline. ApoE4 allele status was defined as 
having one or more ApoE4 alleles.
Statistical Analyses
Baseline characteristics including age, education, functional activities questionnaire, 
polyphramacy, ApoE4 genotype, diagnosis of MCI, diagnosis of AD and Alzheimer’s, 
Antidepressants, Antipsychotics, Antihypertensives, Benzodiazepine and Diabetes 
medication use were compared with t-test (or chi-squared test as appropriate) between 
subjects with and without a fall. Cox proportional hazards models were conducted to 
evaluate the association between subject characteristics and hazard of first fall from entry 
into ADNI. Univariate cox proportional hazard models were fitted. Potential risk factors 
with p <= 0.15 were considered in a stepwise selection to search for the final model. All 
analyses are performed using SAS 9.2 (SAS Institute, Cary, North Carolina).
Results
The cohort was composed of 226 healthy individuals, 400 with MCI, and 184 with mild AD. 
A maximum of 12 assessments per participant were made per protocol over a maximum 
period of 54 months. Average follow up time was 31 months (range 0–54 months). The 
baseline characteristics of subjects who fell and who did not fall during follow up in the 810 
participants from ADNI are presented in Table 1. The age of participants who fell 
(76.80± 6.31) was significantly (p=0.0001) higher than those who did not fall (74.72 ±6.92). 
There was borderline significant association between Beers list and fall 57/212 (27%) for 
participants who fell and 122/598 (20%) for participants who did not fall, (p=0.05).
Furthermore, Cox proportional hazards models were fitted to assess the association between 
patient characteristics and hazard of first fall (Table 2). In the univariate Cox models, the 
effect of each patient characteristic was evaluated individually. Variables significantly or 
borderline significantly associated with time to first fall included age (P = 0.0001, hazard 
ratio [HR]: 1.043 and confidence interval [CI]: 1.04 – 1.07), functional activities 
questionnaire (p = 0.035, HR: 1.023 and CI: 1.00–1.04), Beers list (P = 0.0668, HR: 1.328 
and CI: 0.98 – 1.80), treatment with Alzhemier’s medications for cognitive symptoms (P = 
0.0019, HR: 1.545 and CI: 1.17 – 2.03), treatment with antidepressants (P = 0.0759, HR: 
1.308 and CI: 0.97 – 1.76), and treatment with benzodiazepines (P = 0.0583, HR: 1.848 and 
CI: 0.98 – 3.49). These covariates were used to select for a final multivariate model. In the 
final multivariate model, after adjusting for the significant covariates of age (P <0.0001, HR: 
1.05 and CI: 1.02 – 1.07) and Beer’s list (P = 0.0477, HR: 1.36 and CI: 1.00 – 1.84), 
treatment with Alzheimer’s medication (P = 0.0005, HR: 1.63 and CI: 1.24 – 2.14) was 
associated with increased risk for fall. When we separated out the esterase inhibitors from 
memantine and ran the cox model, only the esterase inhibitors persisted in the final 
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multivariate model (P = 0.0012, HR: 1.577 and CI: 1.197 – 2.078). The hazard ratio estimate 
for age is 1.05, meaning that an increase of 1 year in age will increase the hazard rate by 5%. 
Beer’s list medication use increased the hazard rate by 36%. The treatment with Alzheimer’s 
medication increases the hazard rate by 63%. Medication was changed after an adverse fall 
event by the clinician in 9% of the falls. About 7% of the falls were reported as serious and 
6% reported as severe.
Discussion
Falls due to polypharmacy are well known in the elderly. In one recent study the most 
frequent cause of hospitalization among subjects with Alzheimer’s was fracture and fall not 
causing fracture (9). Dementia compounds the risk of falling by impairing judgment, gait, 
visual-spatial perception, and the ability to recognize and avoid hazards (1, 10, 11) in either 
clinical trials or longitudinal reports. Despite the increasing use of ChEIs and memantine in 
MCI and AD there is limited evidence associating their use with falls as a major adverse 
effect. In the literature there is some suggestion that ChEIs can improve gait and balance 
control by their positive effects on attention and executive functions, which may lead to a 
reduction in falls (5), but several case reports of falls, syncope, and accidental injuries 
related to ChEIs and memantine have been reported (12, 13). Donepezil has been possibly 
related to syncope (14) and syncope could have caused a fall. A recent meta-analysis of 
randomized control trials of dementia medications suggests that ChEIs may increase the risk 
of syncope by 53% with no effects on falls, fracture, or accidental injury in cognitively 
impaired older adults while memantine may have a favorable effect on fracture, with no 
effects on other events (15, 16). Our data would indicate patients on Alzheimer medication 
have a 63% greater chance of falling with time than those not treated with those medications 
which is similar in magnitude to the increase in the risk of syncope noted by others. Our 
study did not show an association between falls and antidepressants but this may have been 
due to ADNI exclusion of subjects taking antidepressants with anticholinergic properties.
Contrary to some of the reports mentioned above we have found a significant association 
between falls and Alzheimer’s medications in a clinical practice setting. Medication 
effectiveness is based on the balance between their benefits and adverse effects. Oftentimes 
clinical trials and registration studies with fairly restrictive inclusion and exclusion criteria 
may not encounter adverse events which occur during medication utilization in clinical 
practice. Limitations of this study include unknown confounders such as selection bias due 
to sampling, clinical susceptibility, medication indication, recall and possibly inconsistent 
adverse event reporting by study personnel. Falls prior to entry into ADNI were not recorded 
and could have been a confounder and possible indication for initiation of Alzheimer’s 
treatment. While this analysis was pre-specified, multiple comparisons could also have led 
to spurious findings. Finally, we may have included unknown intrinsic causes of fall in our 
definition of fall. We do not mean to imply that the Alzheimer’s medications are of 
questionable clinical value. We believe the medications for symptomatic treatment of 
Alzheimer’s are limited in their ability to provide symptomatic benefit (17) and so when 
considering drug effectiveness, serious or severe adverse events must be carefully weighed 
against the small benefit derived from use. Additional pharmaco-vigilance of the association 
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between falls and Alzheimer’s medication use is warranted to confirm these findings in other 
cohorts.
Conclusion
This study found an association between treatment with Alzheimer’s medication and a 63% 
increased hazard of fall over time. This finding needs to be confirmed in other cohorts and 
evaluated further as 7% of the falls were serious.
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Table 1
Baseline characteristics of subjects who fell or did not in 810 participants from ADNI.
Characteristics No fall (n=598) Fall (n= 212) P Value
Age [years (+/− SD)] 74.72 (6.92) 76.80 (6.31) 0.00
Male [n (% of cohort)] 354 (59) 117 (55) 0.31
Education [years (+/− SD)] 15.55 (3.06) 15.59 (2.96) 0.86
FAQ [score (+/− SD)] 4.92 (6.56) 4.86 (6.42) 0.90
Co-medications [n (+/− SD)] 7.33 (4.10) 7.74 (3.53) 0.17
APOE carrier [n (% of cohort)] 299 (50) 99 (47) 0.41
Diagnosis MCI [n (% of cohort)] 286 (48) 114 (54) 0.18
Diagnosis AD [n (% of cohort)] 145 (24) 39 (18) 0.18
Medication use
 Alzheimer’s [n (% of cohort)] 256 (43) 103 (49) 0.15
 Antidepressants [n (% of cohort)] 145 (24) 62 (29) 0.15
 Antipsychotics [n (% of cohort)] 3 (1) 2 (1) 0.48
 Antihypertensives [n (% of cohort)] 309 (52) 309 (52) 0.32
 Benzodiazepine [n (% of cohort)] 15 (3) 10 (5) 0.11
 Diabetes’s [n (% of cohort)] 36 (6) 9 (4) 0.33
 Beers list [n (% of cohort)] 122 (20) 57 (27) 0.05
Abbreviations include standard deviation (SD), Alzheimer’s Disease Neuro-imaging initiative (ADNI), functional activities questionnaire (FAQ), 
apolipoprotein E (APOE), mild cognitive impairment (MCI), Alzheimer’s disease (AD),
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